C7A.093
Malignant carcinoid tumor of the kidney
Clinical Classification Guidelines
Medical Intelligence & Overview
A malignant carcinoid tumor of the kidney is a rare type of cancer that originates from neuroendocrine cells within the kidney. These tumors are part of a broader group known as carcinoid tumors, which can develop in various organs but are exceedingly uncommon in the kidney. Due to their malignancy, they can spread to other parts of the body if not diagnosed and treated early. Understanding this condition involves exploring its causes, symptoms, methods of diagnosis, and available treatment options.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting neuroendocrine cells Unknown exact triggers; potential links to genetic syndromes History of other neuroendocrine tumors Chronic kidney disease or other renal abnormalities
Key Symptoms: Flank pain or discomfort A noticeable lump or mass in the kidney region Blood in the urine (hematuria) Unexplained weight loss Fatigue and general weakness Symptoms related to hormone secretion if applicable, such as flushing or diarrhea Fever or night sweats in some cases
Diagnostic & Treatment
Diagnosis Path: Imaging tests such as ultrasound, computed tomography (CT) scans, or magnetic resonance imaging (MRI) help identify the location and size of the tumor. Laboratory tests including urinalysis to detect blood in the urine. Biopsy procedures, often guided by imaging, allow for tissue sampling to confirm malignancy and histological type. Additional tests, such as somatostatin receptor scans, may be employed to evaluate the tumor's neuroendocrine activity. Staging investigations to determine whether the cancer has spread beyond the kidney.
Treatment Protocols: Surgical removal of the tumor, often through partial or complete nephrectomy, is the primary treatment. Systemic therapies, including chemotherapy or targeted therapies, may be recommended based on tumor spread and characteristics. Somatostatin analogs can help control symptoms related to hormone secretion. Radiation therapy might be considered in certain cases to address localized or metastatic disease. Regular follow-up with imaging and laboratory assessments to monitor for recurrence or progression.
Clinical Advice & FAQs
Billing Guidance
Is C7A.093 a billable ICD-10 code?
Yes, C7A.093 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C7A.093?
Clinical documentation must specify the nature of Malignant carcinoid tumor of the kidney and any associated comorbidities for accurate reporting.
Cite this Clinical Reference